Skip to main content
OpenTrials
Completed

NCT Number: NCT02910024

Theta-Burst-Stimulation in Early Rehabilitation of Stroke

The present prospective, randomized, controlled, double-blinded trial investigates the effects of intermittent theta-burst stimulation (iTBS) during the early rehabilitation after stroke. Patients with hemipresis will receive either sham or real iTBS over their affected hemispheres before occupational therapy for 8 days. Motor recovery is assessed one day after the intervention phase and three months after enrollment.

Completed

Looking for future studies?

Notify Me

Key information

Age range

40 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

Klinik und Poliklinik für Neurologie, Universitätsklinikum Köln

Cologne, North Rhine-Westphalia, 50924, Germany

About this study

To date, rehabilitation of stroke with hemiparesis mainly includes physiotherapy and occupational therapy. Yet, the majority of patients retain movement impairment relevant for activities of daily living. One explanation for this deficit is the insufficient recovery of connectivity between brain regions after stroke. It is possible to modulate this process by repetitive transcranial magnetic stimulation (rTMS) using the protocol of intermittent theta-burst stimulation (iTBS). Previous data indicate that modulation of the motor cortex with iTBS enhances the effects of subsequent motor training. The present study aims at investigating whether daily repetitive transcranial magnetic stimulation over 8 days combined with subsequent physiotherapy leads to better motor recovery, compared with physiotherapy after sham stimulation. In the first weeks and after three months, motor function, degree of disability and quality of life are examined in order to evaluate the effects of iTBS in the rehabilitation of stroke patients.

Amendment (approved by the Ethics-Committee of the Medical Faculty of the University of Cologne, 20/12/2016): Specification of exclusion criteria.

Amendment (approved by the Ethics-Committee of the Medical Faculty of the University of Cologne, 15/11/2018): Change of inclusion and exclusion criteria.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • written consent
  • age: 40-90 years
  • ischemic stroke
  • hemiparesis with impaired hand motor function

Exclusion criteria

  • Subjects who are legally detained in an official institute (§20 MPG)
  • Participation in clinical trial within the last 12 weeks
  • Electronic implants or ferromagnetic Implants located in the head, neck or thorax (e.g. clips, intracranial shunt, artificial heart valve, pacemaker)
  • Medication pump (e.g. insulin pump)
  • Metal splinters in eye or head
  • Pregnancy / breastfeeding
  • Severe Neurodegenerative disease
  • Severe Neuroinflammatory disease
  • History of seizures / epilepsy
  • Physical addiction to alcohol, medication, or drugs (excluded: nicotine)
  • Insufficient compliance
  • Present or past malignant tumor involving the central nervous system
  • Severe Psychiatric disease
  • Clinically manifest bilateral hemiparesis or infarcts in the primary motor cortex or along the tractus corticospinalis in the hemisphere ipsilateral to the hemiparesis
  • Pre-existing cerebral infarctions with hemiparesis or pre-existing cerebral infarctions in the primary motor cortex or along the tractus corticospinalis, excluding microangiopathic changes (e.g. clinically asymptomatic lacunae <1cm)
  • Known brain lesion (surgical, traumatic)
  • Evidence for enhanced cerebral pressure
  • Severe cardial dysfunction
  • life expectancy < 12 months
  • NIHSS Score > 20
  • Blood glucose imbalances resistant to treatment (<50 mg/dl or >300 mg/dl)
  • Elevated blood pressure resistant to treatment (RR > 185/110mmHg)
  • Systemic Thrombolysis using r-tPA or thrombectomy within the last 24 hours before enrollment in study
  • Medication with benzodiazepines, high-potency antipsychotics or tricyclic antidepressants before hospitalization or long-term during hospitalization

Treatment and study plan

Magstim Super Rapid2 System, intermittent theta-burst-stimulation (iTBS) protocol

Device

iTBS applied over ipsilesional M1

Magstim Super Rapid2 System, sham-stimulation (in iTBS)

Device

iTBS applied with tilted coil over parieto-occipital vertex

Primary outcomes

  1. Relative grip force

    Time frame: 3 months after enrollment

    grip force as measured with vigorimeter

Secondary outcomes

  1. Relative grip force

    Time frame: after 8 days of intervention, and 3 months after enrollment

    grip force as measured with vigorimeter

  2. Motor function

    Time frame: after 8 days of intervention, and 3 months after enrollment

    Action Research Arm Test, ARAT

  3. Motor function

    Time frame: after 8 days of intervention, and 3 months after enrollment

    Fugl-Meyer Motor Scale of the upper extremity, FM

  4. Stroke severity

    Time frame: after 8 days of intervention, and 3 months after enrollment

    National Instituts of Health Stroke Scale, NIHSS

  5. Degree of disability

    Time frame: after 8 days of intervention, and 3 months after enrollment

    modified Rankin Scale, mRS

  6. Motorcortex excitability

    Time frame: after 8 days of intervention, and 3 months after enrollment

    Motor evoked potential induced by stimulation of the affected motor cortex, MEP

  7. Motorcortex excitability

    Time frame: after 8 days of intervention, and 3 months after enrollment

    Resting motor threshold as measured by stimulation of the affected motor cortex, RMT

  8. Quality of life

    Time frame: after 8 days of intervention, and 3 months after enrollment

    EuroQol 5D questionnaire, EQ-5D

  9. Activities of daily living at admission and discharge in external rehabilitation facility

    Time frame: 3 months after enrollment

    Barthel-Index (BI) scores as documented by external rehabilitation facility

  10. Days of rehabilitation after intervention phase

    Time frame: 3 months after enrollment

    Days of rehabilitation after intervention phase as documented by external rehabilitation facility

Sponsors and collaborators

Lead sponsor

University of Cologne

Other

Registry information

Official study title

Theta-Burst-Stimulation in Der frühen Rehabilitation Von Schlaganfallpatienten

Acronym: TheSiReS

Important dates

Study start
2016
Primary completion
2022
Study completion
2022
First posted
Sep 21, 2016
Registry last updated
Sep 21, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.